Abstract
Fulminant Type 1 diabetes is a novel subtype of Type 1 diabetes. In this disease, extremely rapid and almost complete β-cell destruction occurs, resulting in nearly no residual insulin secretion even just after the onset. The number of patients presumably amounts to 5,000∼7,000 in Japan. The involvement of both, genetic background and viral infection, has been suggested in the pathogenesis of this disease. Diagnostic criteria were established by a committee of the japan Diabetes Society in 2004. Intensive insulin therapy is a standard therapy. We should pay special attention to early development of microvascular complications in fulminant type 1 diabetes.
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
Keywords
- Intensive Insulin Therapy
- Continuous Subcutaneous Insulin Infusion
- Autoimmune Pancreatitis
- Continuous Glucose Monitoring System
- Japan Diabetes Society
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Imagawa A, Hanafusa T, Miyagawa J et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med 2000; 342:301–307.
Hanafusa T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab 2007; 3:36–45.
Imagawa A, Hanafusa T, Uchigata Y et al. Fulminant type 1 diabetes: a nationwide survey in japan. Diabetes Care 2003; 26:2345–2352.
Imagawa A, Hanafusa T, Uchigata Y et al. Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. Diabetologia 2005; 48:294–300.
Kawasaki E, Imagawa A, Makino H et al. Differences in the contribution of CTLA4 gene to susceptibility to fulminant and type 1A diabetes in japanese patients. Diabetes Care 2008; 31:1608–1610.
Kawabata Y, Ikegami H, Awata T et al. Differential association ofhla with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia 2009; 52:2513–2521.
Hanafusa T, Imagawa A, Iwahashi H et al. Report of the Japan Diabetes Society’s committee on research on fulminant type 1 diabetes mellitus: analysis of antiviral antibodies at disease onset. J Japan Diab Soc 2008; 51:531–536.
Shibasaki S, Imagawa A, Tauriainen S et al. Expression of Toll-like receptors in the pancreas of recent-onset fulminant type 1 diabetes. Endocrine J 2010; 57:211–219.
Aida K, Nishida Y, tanaka S et al. RIG-and MDA5-initiated innate immunity linked with adaptive immunity accelerates β-cell death in fulminant type 1 diabetes. Diabetes 2011; 60:884–889.
Kotani R, Nagata M, Imagawa A et al. T-lymphocyte response against pancreatic beta cell antigens in fulminant type 1 diabetes Diabetologia 2004; 47:1285–1291.
Tanaka S, Nishida Y, Aida K et al. Enterovirus infection, CXC chemokine ligand 10 (CXCl10) and CXCR3 circuit: a mechanism of accelerated beta-cell failure in fulminant type 1 diabetes. Diabetes 2009; 58:2285–2291.
Endo T, Takizawa S, Tanaka S et al. Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes. Diabetes 2009; 58:732–737.
Takizawa S, Endo T, Wanjia X et al. HSP 10 is a new autoantigen in both autoimmune pancreatitis and fulminant type 1 diabetes. Biochem Biophys Res Commun2009; 386:192–196.
Shibasaki S, Imagawa A, Terasaki J et al. Endogenous insulin secretion even at a very low level contributes to the stability of blood glucose control in fulminant type 1 diabetes. J Diab Invest 2010; 1:283–285.
Murase Y, Imagawa A, Hanafusa T, et al. Fulminant type 1 diabetes as a high risk group for diabetic microangiopathy-a nationwide 5-year-study in Japan. Diabetologia 2007; 50:531–537.
Sano H, Terasaki J, Mishiba Y et al. Exenatide, glucagon-like peptide-1 receptor agonist suppresses pancreatic β-cell destruction induced by encephalomyocarditis virus. Biochem Biophys Res Commun 2011; 404:756–761.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Shibasaki, S., Imagawa, A., Hanafusa, T. (2013). Fulminant Type 1 Diabetes Mellitus. In: Ahmad, S.I. (eds) Diabetes. Advances in Experimental Medicine and Biology, vol 771. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5441-0_3
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5441-0_3
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5440-3
Online ISBN: 978-1-4614-5441-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)